Results of the National Cancer Institute early breast cancer trial.

K. Straus, A. Lichter, Marc E Lippman, D. Danforth, S. Swain, K. Cowan, E. deMoss, H. MacDonald, S. Steinberg, T. d'Angelo

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

In 1979, a prospective, randomized trial was begun at the National Cancer Institute comparing lumpectomy, axillary dissection, and radiation therapy (XRT) to modified radical mastectomy for the treatment of invasive breast cancer, clinical stage T1-2, N0-1, M0. Treatment in the radiation arm consisted of full axillary dissection and gross removal of the tumor, followed by 4500 to 5000 cGy to the whole breast and a boost to the tumor bed of 1500 to 2000 cGy. Patients with positive axillary dissections received radiation to the supraclavicular nodes, in addition to cyclophosphamide and doxorubicin. Two hundred thirty-seven patients entered in the trial between 1979 and 1987 are available for analysis, 116 in the mastectomy arm and 121 in the radiation arm. With a median follow-up of 67.7 months, there are no significant differences in 5-year overall survival (85% vs 89%, mastectomy vs radiation) or 5-year disease-free survival (82% vs 72%, mastectomy vs radiation). Patients in the radiation arm had an actuarial in-breast recurrence rate of 12% at 5 years and 20% at 8 years. There were no major differences between complication rates in the treatment arms. The results of the study indicate that patients with invasive breast cancer, stage I and II, can be treated with lumpectomy, axillary dissection, and radiation therapy with results comparable to those with modified radical mastectomy.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalJournal of the National Cancer Institute. Monographs
Issue number11
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Radiation
Breast Neoplasms
Arm
Dissection
Mastectomy
Modified Radical Mastectomy
Segmental Mastectomy
Breast
Radiotherapy
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Neoplasms
Therapeutics
Recurrence
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Straus, K., Lichter, A., Lippman, M. E., Danforth, D., Swain, S., Cowan, K., ... d'Angelo, T. (1992). Results of the National Cancer Institute early breast cancer trial. Journal of the National Cancer Institute. Monographs, (11), 27-32.

Results of the National Cancer Institute early breast cancer trial. / Straus, K.; Lichter, A.; Lippman, Marc E; Danforth, D.; Swain, S.; Cowan, K.; deMoss, E.; MacDonald, H.; Steinberg, S.; d'Angelo, T.

In: Journal of the National Cancer Institute. Monographs, No. 11, 01.01.1992, p. 27-32.

Research output: Contribution to journalArticle

Straus, K, Lichter, A, Lippman, ME, Danforth, D, Swain, S, Cowan, K, deMoss, E, MacDonald, H, Steinberg, S & d'Angelo, T 1992, 'Results of the National Cancer Institute early breast cancer trial.', Journal of the National Cancer Institute. Monographs, no. 11, pp. 27-32.
Straus K, Lichter A, Lippman ME, Danforth D, Swain S, Cowan K et al. Results of the National Cancer Institute early breast cancer trial. Journal of the National Cancer Institute. Monographs. 1992 Jan 1;(11):27-32.
Straus, K. ; Lichter, A. ; Lippman, Marc E ; Danforth, D. ; Swain, S. ; Cowan, K. ; deMoss, E. ; MacDonald, H. ; Steinberg, S. ; d'Angelo, T. / Results of the National Cancer Institute early breast cancer trial. In: Journal of the National Cancer Institute. Monographs. 1992 ; No. 11. pp. 27-32.
@article{e2d6ab3408014e2b8fa6520c6abb38f5,
title = "Results of the National Cancer Institute early breast cancer trial.",
abstract = "In 1979, a prospective, randomized trial was begun at the National Cancer Institute comparing lumpectomy, axillary dissection, and radiation therapy (XRT) to modified radical mastectomy for the treatment of invasive breast cancer, clinical stage T1-2, N0-1, M0. Treatment in the radiation arm consisted of full axillary dissection and gross removal of the tumor, followed by 4500 to 5000 cGy to the whole breast and a boost to the tumor bed of 1500 to 2000 cGy. Patients with positive axillary dissections received radiation to the supraclavicular nodes, in addition to cyclophosphamide and doxorubicin. Two hundred thirty-seven patients entered in the trial between 1979 and 1987 are available for analysis, 116 in the mastectomy arm and 121 in the radiation arm. With a median follow-up of 67.7 months, there are no significant differences in 5-year overall survival (85{\%} vs 89{\%}, mastectomy vs radiation) or 5-year disease-free survival (82{\%} vs 72{\%}, mastectomy vs radiation). Patients in the radiation arm had an actuarial in-breast recurrence rate of 12{\%} at 5 years and 20{\%} at 8 years. There were no major differences between complication rates in the treatment arms. The results of the study indicate that patients with invasive breast cancer, stage I and II, can be treated with lumpectomy, axillary dissection, and radiation therapy with results comparable to those with modified radical mastectomy.",
author = "K. Straus and A. Lichter and Lippman, {Marc E} and D. Danforth and S. Swain and K. Cowan and E. deMoss and H. MacDonald and S. Steinberg and T. d'Angelo",
year = "1992",
month = "1",
day = "1",
language = "English",
pages = "27--32",
journal = "NCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Results of the National Cancer Institute early breast cancer trial.

AU - Straus, K.

AU - Lichter, A.

AU - Lippman, Marc E

AU - Danforth, D.

AU - Swain, S.

AU - Cowan, K.

AU - deMoss, E.

AU - MacDonald, H.

AU - Steinberg, S.

AU - d'Angelo, T.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - In 1979, a prospective, randomized trial was begun at the National Cancer Institute comparing lumpectomy, axillary dissection, and radiation therapy (XRT) to modified radical mastectomy for the treatment of invasive breast cancer, clinical stage T1-2, N0-1, M0. Treatment in the radiation arm consisted of full axillary dissection and gross removal of the tumor, followed by 4500 to 5000 cGy to the whole breast and a boost to the tumor bed of 1500 to 2000 cGy. Patients with positive axillary dissections received radiation to the supraclavicular nodes, in addition to cyclophosphamide and doxorubicin. Two hundred thirty-seven patients entered in the trial between 1979 and 1987 are available for analysis, 116 in the mastectomy arm and 121 in the radiation arm. With a median follow-up of 67.7 months, there are no significant differences in 5-year overall survival (85% vs 89%, mastectomy vs radiation) or 5-year disease-free survival (82% vs 72%, mastectomy vs radiation). Patients in the radiation arm had an actuarial in-breast recurrence rate of 12% at 5 years and 20% at 8 years. There were no major differences between complication rates in the treatment arms. The results of the study indicate that patients with invasive breast cancer, stage I and II, can be treated with lumpectomy, axillary dissection, and radiation therapy with results comparable to those with modified radical mastectomy.

AB - In 1979, a prospective, randomized trial was begun at the National Cancer Institute comparing lumpectomy, axillary dissection, and radiation therapy (XRT) to modified radical mastectomy for the treatment of invasive breast cancer, clinical stage T1-2, N0-1, M0. Treatment in the radiation arm consisted of full axillary dissection and gross removal of the tumor, followed by 4500 to 5000 cGy to the whole breast and a boost to the tumor bed of 1500 to 2000 cGy. Patients with positive axillary dissections received radiation to the supraclavicular nodes, in addition to cyclophosphamide and doxorubicin. Two hundred thirty-seven patients entered in the trial between 1979 and 1987 are available for analysis, 116 in the mastectomy arm and 121 in the radiation arm. With a median follow-up of 67.7 months, there are no significant differences in 5-year overall survival (85% vs 89%, mastectomy vs radiation) or 5-year disease-free survival (82% vs 72%, mastectomy vs radiation). Patients in the radiation arm had an actuarial in-breast recurrence rate of 12% at 5 years and 20% at 8 years. There were no major differences between complication rates in the treatment arms. The results of the study indicate that patients with invasive breast cancer, stage I and II, can be treated with lumpectomy, axillary dissection, and radiation therapy with results comparable to those with modified radical mastectomy.

UR - http://www.scopus.com/inward/record.url?scp=0026485973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026485973&partnerID=8YFLogxK

M3 - Article

C2 - 1627428

AN - SCOPUS:0026485973

SP - 27

EP - 32

JO - NCI Monographs

JF - NCI Monographs

SN - 1052-6773

IS - 11

ER -